Drugs that are used to treat RHEUMATOID ARTHRITIS.
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.
Organic compounds that contain GOLD as an integral part of the molecule. Some are used as ANTIRHEUMATIC AGENTS. The term chrysotherapy derives from an ancient Greek term for gold.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.
A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.
Therapy with two or more separate preparations given for a combined effect.
A subspecialty of internal medicine concerned with the study of inflammatory or degenerative processes and metabolic derangement of connective tissue structures which pertain to a variety of musculoskeletal disorders, such as arthritis.
3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
Roentgenography of a joint, usually after injection of either positive or negative contrast medium.
Also known as articulations, these are points of connection between the ends of certain separate bones, or where the borders of other bones are juxtaposed.
Antibodies found in adult RHEUMATOID ARTHRITIS patients that are directed against GAMMA-CHAIN IMMUNOGLOBULINS.
A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.
The articulations extending from the ANKLE distally to the TOES. These include the ANKLE JOINT; TARSAL JOINTS; METATARSOPHALANGEAL JOINT; and TOE JOINT.
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The articulations extending from the WRIST distally to the FINGERS. These include the WRIST JOINT; CARPAL JOINTS; METACARPOPHALANGEAL JOINT; and FINGER JOINT.
Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.
A plant genus of the family CELASTRACEAE that is a source of triterpenoids and diterpene epoxides such as triptolide.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
Inflammation of a synovial membrane. It is usually painful, particularly on motion, and is characterized by a fluctuating swelling due to effusion within a synovial sac. (Dorland, 27th ed)
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
An agency of the PUBLIC HEALTH SERVICE established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery..." It supersedes the National Center for Health Services Research. The United States Agency for Health Care Policy and Research was renamed Agency for Healthcare Research and Quality (AHRQ) under the Healthcare Research and Quality Act of 1999.
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
Antibodies produced by a single clone of cells.
The inner membrane of a joint capsule surrounding a freely movable joint. It is loosely attached to the external fibrous capsule and secretes SYNOVIAL FLUID.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
Measurement of rate of settling of erythrocytes in anticoagulated blood.
Substances that reduce or suppress INFLAMMATION.
A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.
Arthritis of children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL).
A ligand that binds to but fails to activate the INTERLEUKIN 1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
The joint that is formed by the distal end of the RADIUS, the articular disc of the distal radioulnar joint, and the proximal row of CARPAL BONES; (SCAPHOID BONE; LUNATE BONE; triquetral bone).
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
The articulation between the head of one phalanx and the base of the one distal to it, in each finger.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Methods to determine in patients the nature of a disease or disorder at its early stage of progression. Generally, early diagnosis improves PROGNOSIS and TREATMENT OUTCOME.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
Elements of limited time intervals, contributing to particular results or situations.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
The level of health of the individual, group, or population as subjectively assessed by the individual or by more objective measures.
Determination of the degree of a physical, mental, or emotional handicap. The diagnosis is applied to legal qualification for benefits and income under disability insurance and to eligibility for Social Security and workmen's compensation benefits.
Research techniques that focus on study designs and data gathering methods in human and animal populations.
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
A plasma protein that circulates in increased amounts during inflammation and after tissue damage.
A class of statistical methods applicable to a large set of probability distributions used to test for correlation, location, independence, etc. In most nonparametric statistical tests, the original scores or observations are replaced by another variable containing less information. An important class of nonparametric tests employs the ordinal properties of the data. Another class of tests uses information about whether an observation is above or below some fixed value such as the median, and a third class is based on the frequency of the occurrence of runs in the data. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1284; Corsini, Concise Encyclopedia of Psychology, 1987, p764-5)
Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Patterns of practice related to diagnosis and treatment as especially influenced by cost of the service requested and provided.

Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. (1/3077)

OBJECTIVE: To investigate the usefulness of hydroxychloroquine (HCQ) dose-loading to increase the percentage of responders or rate of response in treating rheumatoid arthritis (RA). METHODS: Two hundred twelve patients with early RA (mean duration 1.5 years) were enrolled in a 24-week trial. Patients were stabilized with 1,000 mg naproxen/day and then began a 6-week, double-blind trial comparing treatment with HCQ at 400 mg/day (n = 71), 800 mg/day (n = 71), and 1,200 mg/day (n = 66), followed by 18 weeks of open-label HCQ treatment at 400 mg/day. RESULTS: All patients had mild, active disease at the time of initiation of HCQ treatment (31-43% rheumatoid factor positive; no previous disease-modifying antirheumatic drugs; mean swollen joint count 8.6-10.4). Based on the Paulus criteria, response during the 6-week double-blind portion of the study was 47.97%, 57.7%, and 63.6% in the 400 mg/day, 800 mg/day, and 1,200 mg/day groups, respectively (P = 0.052). Discontinuations for adverse events were dose related (3 in the 400 mg/day group, 5 in the 800 mg/day group, 6 in the 1,200 mg/day group). Most involved the gastrointestinal (GI) system, with the background naproxen treatment possibly contributing. Ocular abnormalities occurred in 17 of 212 patients (8%) but were not dose related. CONCLUSION: Dose-loading with HCQ increased the degree of response at 6 weeks in this group of patients with early, predominantly seronegative RA. Adverse GI events were dose related, while adverse ocular events were not.  (+info)

Inhibition of IL-6 and IL-8 induction from cultured rheumatoid synovial fibroblasts by treatment with aurothioglucose. (2/3077)

Gold compounds have long been used in the treatment of rheumatoid arthritis (RA). However, their actions in RA have not been clarified. In this study, we examined the effect of one of the monovalent gold compounds, aurothioglucose (AuTG), on the IL-1-induced production of IL-6, IL-8 and granulocyte macrophage colony stimulating factor (GM-CSF) from rheumatoid synovial fibroblasts (RSF) isolated from three RA patients. IL-6 and IL-8 induction but not GM-CSF induction was inhibited in most of the RSF after pretreatment with AuTG. Since gene expression of these cytokines is known to be under the control of a common transcription factor, NF-kappaB, the effect of AuTG on the cellular localization of NF-kappaB (p65 subunit) and on NF-kappaB-DNA binding was examined. Although AuTG treatment did not prevent NF-kappaB nuclear translocation, AuTG blocked the DNA-binding activity of NF-kappaB when examined in vitro. Morphologically, both metal-specific cell staining using p-dimethylaminobenzylidene rhodamine and transmission electron microscopic examinations demonstrated the accumulation of metal gold in the cytoplama and some organella (mitochondria and lysosomes) of the AuTG-treated RSF. These results indicate that one of the anti-rheumatic actions of AuTG might be through its inhibitory action on NF-kappaB.  (+info)

Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. (3/3077)

OBJECTIVE: To determine the role of interleukin-1 receptor antagonist (IL-1Ra) in rat adjuvant arthritis and rat type II collagen-induced arthritis, and to compare the efficacy in rat models with that seen in human clinical trials of IL-1Ra. METHODS: Rats with developing adjuvant arthritis or established collagen-induced arthritis were treated with IL-1Ra by continuous infusion in order to determine and maintain efficacious blood levels of this IL-1 inhibitory protein in the rats for comparison with human clinical data. The effects of treatment in the rats were monitored by sequential caliper measurement of the ankle joints, determination of final paw weights, and histologic evaluation with particular emphasis on bone and cartilage lesions. The effects of IL-1Ra on joint swelling and radiographic bone damage in patients with rheumatoid arthritis (RA) in a 6-month trial were compared with the findings in rats. RESULTS: Dramatic differences in the profile of IL-1Ra activity were seen between the 2 groups of rats. Modest antiinflammatory effects were observed in the adjuvant arthritis rats treated with IL-1Ra. However, marked inhibition of bone resorption occurred, even at doses with which antiinflammatory activity was not seen. In contrast, IL-1Ra treatment of rats with established collagen-induced arthritis resulted in nearly complete suppression of all aspects of the disease when adequate blood levels of IL-1Ra were maintained. Treatment of RA patients with IL-1Ra (150 mg daily) resulted in modest inhibition of joint swelling and inhibition of radiographic progression of bone lesions. CONCLUSION: IL-1 appears to be of major importance in mediating the bone resorption that occurs in rat adjuvant arthritis, but is less important in the pathogenesis of periarticular inflammation in this disease. In contrast, IL-1 is of major importance in mediating all aspects of disease progression in rat collagen-induced arthritis. Similar to the response in adjuvant arthritic rats, RA patients treated with IL-1Ra showed only modest antiinflammatory activity, but had evidence of inhibition of progression of bone resorption. However, a comparison of the plasma levels of IL-1Ra in humans and rats suggests that the optimal level of dosing for continuous saturation of IL-1 receptors may not have been achieved in humans, although this was achieved in the rat studies.  (+info)

Effect of its demethylated metabolite on the pharmacokinetics of unchanged TAK-603, a new antirheumatic agent, in rats. (4/3077)

A factor in the dose-dependent pharmacokinetics of ethyl 4-(3, 4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2, 4-triazol-1-yl-methyl)quinoline-3-carboxylate (TAK-603) in rats was shown to be due to the inhibition of metabolic clearance of unchanged TAK-603 by its major metabolite, M-I, in other words, product inhibition. The effect of M-I on the metabolic clearance of TAK-603 was studied using rats continuously infused i.v. with this metabolite at rates of 5.3 and 16.0 mg/h/kg. The total body clearance of TAK-603 was decreased remarkably in M-I-infused rats, and the decline of total body clearance depended on the steady-state plasma concentrations of M-I. The effect of M-I generated from the dosed parent drug on the plasma concentration-time profile of TAK-603 was investigated using bile-cannulated rats after i.v. injection of 14C-labeled TAK-603 at doses of 1 and 15 mg/kg. Elimination rates of TAK-603 from rat plasma increased in the bile-cannulated rats in which systemic M-I levels were reduced by interrupting its enterohepatic circulation. To express, simultaneously, the relationships between TAK-603 and M-I in plasma concentration-time profiles, a kinetic model based on the product inhibition was developed for the bile-cannulated rats. A good agreement between calculated curves and the observed concentrations of both TAK-603 and M-I was found at 1 and 15 mg/kg, and the calculated curves were drawn using constant parameters for the two dosages. These results show that the product inhibition by M-I is one factor responsible for the dose-dependent pharmacokinetics of TAK-603 in rats.  (+info)

High and low molecular weight DNA cleavage in ovarian granulosa cells: characterization and protease modulation in intact cells and in cell-free nuclear autodigestion assays. (5/3077)

To continue elucidation of the biochemical and molecular pathways involved in the induction of apoptosis in granulosa cells (GC) of ovarian follicles destined for atresia, we characterized the occurrence and protease modulation of high and low molecular weight (MW) DNA fragmentation during rat GC death. Atresia of ovarian follicles, occurring either spontaneously in vivo or induced in vitro, was associated with both high MW and internucleosomal (low MW) DNA cleavage. Incubation of follicles in the presence of a putative irreversible and non-competitive inhibitor of caspase-1 (interleukin-1beta-converting enzyme or ICE), sodium aurothiomalate (SAM), completely prevented internucleosomal, but not high MW, DNA cleavage. As reported previously, morphological features of apoptosis (pyknosis, cellular condensation) and atresia (granulosa cell disorganization, oocyte pseudomaturation) remained detectable in SAM-treated follicles. The potential involvement of proteases in endonuclease activation was further analyzed in cell-free assays using nuclei from both GC (which autodigest their DNA) and HeLa cells (HC, which do not autodigest their DNA unless incubated with extracts prepared from other cell types). Crude cytoplasmic extracts prepared from GC induced both high MW and internucleosomal DNA cleavage in HC nuclei. The induction of low, but not high, MW DNA cleavage in HC nuclei by GC extracts was suppressed by pretreatment of the extracts with SAM or with any one of the serine protease inhibitors, dichloroisocoumarin (DCI), N-tosyl-L-leucylchloromethylketone (TLCK) or N-tosyl-L-phenylchloromethylketone (TPCK). Interestingly, SAM and DCI also prevented cation-induced low MW DNA fragmentation in GC nuclei; however, TLCK and TPCK were without effect. Our results support a role for cytoplasmic and nuclear serine proteases in the activation of the endonuclease(s) responsible for internucleosomal DNA cleavage during apoptosis.  (+info)

Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate. (6/3077)

OBJECTIVE: To confirm the impression of a better outcome of patients withdrawn from parenteral gold salt therapy compared with those withdrawn from methotrexate. METHODS: Patients with early, active, and erosive RA were randomised for a double blind trial to receive either weekly 15 mg intramuscular methotrexate or 50 mg goldsodiumthiomalate. If the drug had to be withdrawn because of side effects treatment was continued with the other drug in still active disease. Patients with insufficient response were treated with a combination of both drugs. All patients were followed up by an extended clinical and radiographic evaluation. RESULTS: 64 patients each were allocated to methotrexate and gold treatment. After 72 months a complete record was available for 88% of patients. Within the first 36 months 38 patients withdrew from gold treatment (95% because of side effects) and 23 patients withdrew from methotrexate (57% because of side effects). A significant 40% to 70% improvement of all parameters (erythrocyte sedimentation rate, C reactive protein, swollen and tender joints, radiological progression) compared with baseline was observed in patients completing their randomised treatment with gold or methotrexate. The same improvement over three years was seen in patients who withdrew from gold treatment, while patients withdrawing from methotrexate experienced a deterioration of their disease. CONCLUSION: Withdrawals represent the majority of patients in long term drug trials. Patients with early RA stopping gold because of side effects show almost the same sustained improvement as patients continuing gold or methotrexate. Patients withdrawn from methotrexate experience a reactivation of their disease.  (+info)

Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. (7/3077)

BACKGROUND: Sulphasalazine (SSZ) has been reported to cause drug induced systemic lupus erythematosus (SLE), but diagnosis of this complication in the context of rheumatoid arthritis (RA) is difficult. OBJECTIVE: To determine prospectively: (1) if patients become seropositive for antinuclear antibodies (ANA) during prolonged treatment with SSZ without clinical evidence of SLE; (2) if ANA positive patients develop more adverse reactions than ANA negative patients; (3) if drug induced SLE was identified in this cohort. METHODS: 200 patients enrolled in a randomised prospective trial of SSZ and auranofin (AUR) were followed up for five years. Baseline and annual ANA results were collected along with information on drug toxicity and reasons for discontinuation of treatment. RESULTS: Over five years 24 patients stopped taking SSZ and 49 AUR because of side effects. Of the features common to SLE, rash developed in nine SSZ patients and 11 AUR treated patients and mouth ulcers in three and four patients respectively. Six SSZ treated patients and three treated with AUR developed leucopenia, which promptly resolved with drug withdrawal. No adverse event was ascribed to drug induced SLE. Of the 72 SSZ treated patients who were ANA negative or weakly positive at outset, 14 (19%) became strongly ANA positive compared with 11 (14%) of 80 AUR patients. Patients ANA positive at baseline or who became ANA positive were not more likely to develop drug toxicity or to withdraw from treatment than those ANA negative throughout. CONCLUSION: ANA positivity is common in patients with RA, but the presence or development of ANA did not increase the likelihood of withdrawing from treatment. No case of drug induced SLE was seen over five years in this study.  (+info)

In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. (8/3077)

The goal of this study was to determine the efficacy of local IL-1Ra gene therapy by intra-articular plasmid injections on structural changes in the meniscectomy rabbit model of osteoarthritis. A partial meniscectomy of the right knee was performed on the rabbits through a medial parapatellar incision. The rabbits were then divided into four experimental groups. Group 1 received no treatment. Group 2 received three consecutive intra-articular injections at 24-hour intervals of 0.9% saline containing a lipid, gammaAP-DLRIE/DOPE, and a DNA plasmid, VR1012. Group 3 received three consecutive injections of saline containing 1000 microg of canine IL-1Ra plasmid and lipid. The injections were given starting 4 weeks post-surgery. Rabbits from Group 1 were killed 4 weeks post-surgery, and all other rabbits 8 weeks post-surgery. The severity of macroscopic and microscopic changes on cartilage on the medial and femoral condyles and tibial plateaus and synovium were graded separately. Specimens were also processed for immunohistochemical staining using a rabbit polyclonal antibody against canine IL-1Ra. The level of canine IL-1Ra in synovial fluid was determined using enzyme-linked immunosorbent assay. The presence of the DNA plasmid in the synovium was tested by polymerase chain reaction. A significant reduction in the width of osteophytes and size of macroscopic lesions (P < 0.04) was observed, and was dependent on the amount of IL-1Ra plasmid injected. A significant reduction was also noted in the severity of histologic cartilage lesions (P < 0.01) in the group that received the highest dosage (1000 microg) of IL-1Ra plasmid. IL-1Ra was detected in synovial fluid by enzyme-linked immunosorbent assay and by immunohistochemical staining in the synovium and cartilage of rabbits that received injections containing the IL-1Ra plasmid. Polymerase chain reaction analysis of synovial DNA revealed the presence of the cloned cDNA dog IL-1Ra up to 4 weeks after the first intra-articular injection. This study demonstrates that direct in vivo transfer of the IL-1Ra gene into osteoarthritis knee cells using intra-articular injections of a plasmid vector and lipids can significantly reduce the progression of experimental osteoarthritis. This avenue may therefore represent a promising future treatment for osteoarthritis.  (+info)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs ...
OBJECTIVES To investigate and compare the risk for malignancy in rheumatoid arthritis (RA) patients treated with biologics in Japan to the general population. METHODS Data for 14,440 patients from 335 institutions who were given infliximab, etanercept, adalimumab, golimumab, tocilizumab, or abatacept were retrieved from the SafEty of biologics in Clinical Use in Japanese patients with RhEumatoid arthritis (SECURE) database. RESULTS We identified 333 incidents of malignancies in 320 patients during 49,320 patient-years (PY). The age- and sex-standardized incidence rate (ASR) (95% confidence interval [CI]) for overall malignancy of the SECURE cohort was 313.9/10(5) PY (271.4-361.3), and the standardized incidence rate ratio (SIR) (95% CI) was 0.745 (0.667-0.826). The ASR was decreased compared to the estimated incidence rate of malignancies in the Japanese general population (462.4/10(5) PY). The SIRs for site-specific nonhematopoietic malignancies of the SECURE cohort were not significantly elevated
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 57, No. 3, April 15, 2007, pp 440 - 447 DOI 10.1002/art.22619 © 2007, American College of Rheumatology ORIGINAL ARTICLE Evaluation of the Preliminary Definitions of Minimal Disease Activity and Remission in an Early Seropositive Rheumatoid Arthritis Cohort DINESH KHANNA,1 MYUNGSHIN OH,2 DANIEL E. FURST,2 VEENA RANGANATH,2 RICHARD H. GOLD,2 JOHN T. SHARP,3 GRACE S. PARK,2 EDWARD C. KEYSTONE,4 AND HAROLD E. PAULUS,2 FOR THE WESTERN CONSORTIUM OF PRACTICING RHEUMATOLOGISTS Objective. To evaluate published proposed definitions of minimal disease activity (MDA) and remission in patients with early rheumatoid arthritis (RA). Methods. The cohort comprised disease-modifying antirheumatic drug (DMARD)-naive patients with early seropositive active RA (n ⴝ 200) treated with traditional DMARDs in the prebiologic era. MDA definitions included Disease Activity Score in 28 joints (DAS28) ,2.85, or achieving 5 of 7 World Health Organization ...
Results Fifty-two percent (n=424) of the 823 patients remained on the first bDMARD and were followed for at least 360 days. Forty-three percent of them (205) were adherent to all prescribed anti-rheumatic medication. CsDMARDs were prescribed to 372 patients of which 53% (196) were adherent while 5% (20) claimed no cdDMARD at all. Methotrexate was the most common csDMARD and was prescribed to 281 patients. The proportions of patients adherent to methotrexate and patients who claimed no methotrexate at all were 60% (170) and 9% (26), respectively. Self-injectable bDMARDs were prescribed to 319 of which 59% (187) were adherent and 8% (25) did not claim any of the prescribed bDMARD. Mean PDC for csDMARDs, methotrexate and self-injectable bDMARDs were 73%, 74% and 74%, respectively. ...
This post marketing observational study will be conducted in cross-sectional, non-interventional, multi-center format in Turkey. As this is a post marketing observational study, Abbott is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.. Subjects will be recruited from rheumatology outpatient clinics of university hospitals and/or private offices.. Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data will be included.. Patient data will be collected with a single visit. During the single visit, all required demographic and clinical data will be recorded on the case report forms by the investigators and every subject will be asked to fill out the Work Productivity and Activity Impairment ...
Objective. To evaluate the cost effectiveness of TNF-α antagonist therapies for rheumatoid arthritis (RA) in the United Kingdom using data from the British Society for Rheumatology Biologics Registry (BSRBR). Methods. A simulation model is constructed to quantify the cost effectiveness of the TNF-α antagonist therapies (infliximab, etanercept and adalimumab) as a group versus traditional disease-modifying anti-rheumatic drugs, with a time horizon over the full patient lifetime. Participants are UK NHS patients in the BSRBR with RA who have failed at least two traditional disease-modifying anti-rheumatic drugs. The BSRBR aims to recruit all RA patients starting on a TNF-α antagonist agent and follows them 6 monthly via consultant and patient administered questionnaires. Data collected include disease activity scores (DAS28), the Health Assessment Questionnaire and the SF-36. Costs include drug, monitoring and hospitalisations. Benefits are measured in disability and quality of life ...
This is a randomized (treatment assigned by chance, like flipping a coin), multicenter, double-blind (neither physician nor patient will know the treatment the patient receives), parallel-group (each group of patients will be treated at the same time) study. JNJ-40346527 will be compared to a placebo, which is an inactive substance used to test whether a drug has a real effect. Patients will receive study medication for 12 weeks and will continue their permitted, stable DMARD therapy (methotrexate [MTX], sulfasalazine [SSZ], and/or hydroxychloroquine [HCQ]) through Week 12. A follow-up visit will occur 4 weeks after dosing is complete. The maximum length of patient participation will be 22 weeks, including a 6-week screening period. Other study visits will occur during the study, and patient safety will be monitored ...
Disease-modifying antirheumatic drugs (DMARDs) is a category of otherwise unrelated drugs defined by their use in rheumatoid arthritis to slow down disease progression. The term is often used in contrast to nonsteroidal anti-inflammatory drug (which refers to agents that treat the inflammation but not the underlying cause) and steroids (which blunt the immune response but are insufficient to slow down the progression of the disease). The term antirheumatic can be used in similar contexts, but without making a claim about an effect on the course. Other terms that have historically been used to refer to the same group of drugs are remission-inducing drugs (RIDs) and slow-acting anti-rheumatic drugs (SAARDs). Although the use of the term DMARDs was first propagated in rheumatoid arthritis (hence their name) the term has come to pertain to many other diseases, such as Crohns disease, lupus erythematosus (SLE), Sjögren syndrome, immune thrombocytopenic purpura (ITP), myasthenia gravis, ...
Muscle atrophy often accompanies RA and is exacerbated by inactivity, bed rest, splints, and medications. Isometric exercises restore and maintain strength in affected patients without producing pain. Resistance exercises may be initiated when the isometric program has been well established and when the patient is free of pain.(5) Occupational therapy also can be very useful for patients with RA.(6). PHARMACOLOGICAL OPTIONS:. Optimal care of patients with rheumatoid arthritis (RA) requires an integrated approach that includes both non-pharmacologic therapies and pharmacologic agents such as non-biologic and biologic disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids.. Medication-based therapies comprise several classes of agents, including non-steroidal anti-inflammatory drugs (NSAIDs), non-biologic and biologic disease-modifying anti-rheumatic drugs (DMARDs), immunosuppressants, and corticosteroids. Early therapy with ...
Objective: Evaluate ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody, effects on radiographic progression in psoriatic arthritis (PsA).. Methods: We conducted preplanned integrated analyses of combined radiographic data from PSUMMIT-1 and PSUMMIT-2 phase 3, randomised, controlled trials. Patients had active PsA despite prior conventional and/or biologic disease-modifying antirheumatic drugs (≥5/66 swollen, ≥5/68 tender joints, C-reactive protein ≥3.0 mg/L, documented plaque psoriasis). Patients (PSUMMIT-1, n=615; PSUMMIT-2, n=312) were randomised to ustekinumab 45 mg, 90 mg, or placebo, at weeks (wk) 0, 4 and every (q) 12 wks. At wk 16, patients with ,5% improvement in tender/swollen joint counts entered blinded early escape. All other placebo patients received ustekinumab 45 mg at wk 24 and wk 28, then q 12 wks. Radiographs of hands/feet at wks 0/24/52 were assessed using PsA-modified van der Heijde-Sharp (vdH-S) scores; combined PSUMMIT-1 and PSUMMIT-2 changes in total vdH-S ...
Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis ...
Risk of solid cancer in patients exposed to anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Mercer, L. et al. Ann Rheum Dis , published on line first 31 March 2014. Authors compared the risk of solid cancer in patients with rheumatoid arthritis treated with TNF inhibitors to that in patients treated with non-biologic (synthetic) disease modifying anti-rheumatic drugs (sDMARDs).. British Society for Rheumatology Biologic Register was established in 2001 to monitor for long-term safety of TNF inhibitors. Patients from that register were followed via record linkage with the national cancer registries until first solid cancer, death, for 5 years or until 2011. Solid cancer rates in 11767 patients without prior cancer treated with TNF inhibitor were compared to those in 3249 patients without prior cancer treated with sDMARDs (ex., methotrexate, sulfasalazine, leflunomide).. 81 cancers per 10000 patient-years were ...
Patients with active rheumatoid arthritis (RA) despite anti-tumor necrosis factor(anti-TNF)agent treatment can switch to either a subsequent anti-TNF agent or a biologic with an alternative mechanism of action, such as rituximab; however, there are limited data available to help physicians decide between these 2 strategies. The objective of this analysis was to examine the effectiveness and safety of rituximab versus a subsequent anti-TNF agent in anti-TNF-experienced patients with RA using clinical practice data from the Corrona registry. Rituximab-naive patients from the Corrona registry with prior exposure to ≥1 anti-TNF agent who initiated rituximab or anti-TNF agents (2/28/2006-10/31/2012) were included. Two cohorts were analyzed: the trimmed population (excluding patients who fell outside the propensity score distribution overlap) and the stratified-matched population (stratified by 1 vs ≥2 anti-TNF agents, then matched based on propensity score). The primary effectiveness outcome was
Patients with active rheumatoid arthritis (RA) despite anti-tumor necrosis factor(anti-TNF)agent treatment can switch to either a subsequent anti-TNF agent or a biologic with an alternative mechanism of action, such as rituximab; however, there are limited data available to help physicians decide between these 2 strategies. The objective of this analysis was to examine the effectiveness and safety of rituximab versus a subsequent anti-TNF agent in anti-TNF-experienced patients with RA using clinical practice data from the Corrona registry. Rituximab-naive patients from the Corrona registry with prior exposure to ≥1 anti-TNF agent who initiated rituximab or anti-TNF agents (2/28/2006-10/31/2012) were included. Two cohorts were analyzed: the trimmed population (excluding patients who fell outside the propensity score distribution overlap) and the stratified-matched population (stratified by 1 vs ≥2 anti-TNF agents, then matched based on propensity score). The primary effectiveness outcome was
Objectives: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARDs). Methods: Patients with active PsA were randomised (1:1) to approved dosing of IXE or ADA in an open-label, head-to-head, blinded assessor clinical trial. The primary objective was to evaluate whether IXE was superior to ADA at week 24 for simultaneous achievement of a ≥50% improvement from baseline in the American College of Rheumatology criteria (ACR50) and a 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI100). Major secondary objectives, also at week 24, were to evaluate whether IXE was: (1) non-inferior to ADA for achievement of ACR50 and (2) superior to ADA for PASI100 response. Additional PsA, skin, treat-to-target and quality-of-life outcome measures were ...
The efficacy of the first bDMARD (biological disease-modifying anti-rheumatic drug) was evaluated in patients with RA following international recommendations on a treat-to-target strategy (n=113) and compared with the delayed initiation of bDMARDs (usual care, n=250) in an outpatient clinic.2 DAS-28 was used to measure disease activity until the end of treatment with the bDMARD. Remission or low disease activity was considered a good response. Treatment efficacy was measured at Months 3, 12, 24 and 36, and at the end of treatment. Kaplan-Meier plots were completed to assess the likelihood of realizing a good response. These plots showed that the likelihood for a good response was significantly higher in the treat-to-target patients (P,0.001).. Efficacy of the three classic bDMARDs, adalimumab, etanercept and infliximab, was comparable. The hazard ratio of the likelihood of achieving a good response was 1.71 (95% CI 1.18-2.47, P=0.004) in favor of the treat-to-target group. A total steroid dose ...
To assess the cost-effectiveness of abatacept compared to different biologic treatment strategies for moderate to severe rheumatoid arthritis based on current medical practices in Canada. A model was constructed to assess the cost-effectiveness of various biologic treatments over a 2-year time horizon, using two effectiveness endpoints: low disease activity state (LDAS) and remission. Abatacept, as first biologic agent after an inadequate response to DMARDs, provides greater treatment success rate for achieving LDAS (29.4% versus 15.6%) and remission (14.8% versus 5.2%), and appears significantly more cost-effective compared to the sequential use of anti-TNF agents (p,0.001). Abatacept, as second biologic agent after an inadequate response to one anti-TNF agent, provides greater treatment success rate for achieving LDAS (17.1% versus 10.2%) and remission (7.4% versus 3.9%) and appears significantly more cost-effective compared to the sequential use of anti-TNF agents (p,0.001). Abatacept is ...
Tocilizumab and the Risk of Cardiovascular Disease (CVD): Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis (RA) Patients. Tocilizumab was associated with a CVD risk comparable to that for etanercept as well as a number of other biologics used for the treatment of RA. PubMed, Arthritis Care Res (Hoboken), 2019 Aug;71(8):1004-1018. (Also see Treatments for Rheumatoid Arthritis and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles ...
(HealthDay)-For older patients with rheumatoid arthritis (RA), there is considerable variation in time to receipt of first biologic disease-modifying antirheumatic drug (DMARD) after prescription of the first conventional synthetic (cs) DMARD, according to a study published online Dec. 6 in JAMA Network Open.
BACKGROUND: Tumour necrosis factor (TNF) is known to increase the concentrations of interleukin (IL) 6 and C reactive protein (CRP) and to induce proatherogenic changes in the lipid profile and may increase the cardiovascular risk of patients with rheumatoid arthritis (RA) and other inflammatory disorders. OBJECTIVE: To assess whether anti-TNF therapy modifies the cardiovascular risk profile in patients with RA. METHODS: The lipoprotein spectrum and the inflammation markers CRP and IL6 were investigated in 33 patients with RA treated with human anti-TNF monoclonal antibodies (D2E7, adalimumab, Humira) and 13 patients with RA given placebo, before and after 2 weeks treatment. RESULTS: In the anti-TNF treated group, the mean (SD) concentrations of HDL-cholesterol were significantly higher after 2 weeks treatment (0.86 (0.30) mmol/l v 0.98 (0.33) mmol/l, p,0.01), whereas LDL and triglyceride levels were not significantly changed. Additionally, a significant decrease in CRP (86.1 (54.4) mg/l v ...
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
OBJECTIVE: To study the risk of a second malignant neoplasm (SMN) and mortality in patients with rheumatoid arthritis (RA) with a history of a primary cancer diagnosis and treated with biological disease-modifying antirheumatic drugs (bDMARD). METHODS: Among patients with RA (n=15 286) registered in the DANBIO Register during 2000-2011, 1678 had a primary cancer according to the Danish Cancer Registry. HRs for SMN and death were calculated. RESULTS: During follow-up there were 279 patients with RA contributing person-years to the bDMARDs use before their primary cancer diagnosis, 220 to the only after, 92 to the both before and after, while 1203 patients with RA contributed to the non-use strata ...
Methotrexate is a commonly-used DMARD which, like the others, reduces the activity of the immune system, resulting in a decrease in the inflammation which drives rheumatological conditions. This helps to prevent underlying joint damage caused by on-going inflammation, as well as easing the symptoms of pain and swelling associated with these conditions. Methotrexate is usually prescribed for people with rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis and vasculitis. It is usually taken once a week in tablet form, although injections are also available. You will need a blood test and a chest X-ray before starting the drug, and the blood tests will continue at regular intervals when taking methotrexate. For more information visit the Arthritis Research UK website.. ...
While still in Florida, they picked up another hitchhiker, Dennis Weaver, who rode with them to Atlanta, where he was let out about 11 pm? Attorney longest dinex uk General Eric Holder authorized a study of racial disparities in the federal death penalty during his tenure as Deputy Attorney General during the Clinton Administration? Similarly, ceftin tablets price excluding patients in whom insomnia developed with fluoxetine or desipramine did not alter the results. Im a 24-year-old male and I got some 0025% Retin-A (Ortho/ johnson&johnson brand) online? I went to the referral and they did thorough research into all my lab tests and came back stating I did not have kidney disease? Only a handful of girls met all the criteria in any given season. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: Part II Safety! Three deltasone 10 tablets price floatingly of these states ...
Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. J Rheumatol 2009; 36: 2397-402 ...
For a complex, progressive, chronic disease such as rheumatoid arthritis, the timing of intervention is critical. In the past, the recommended treatment approach was slow and steady, referred to as the pyramid-ie, a base of physical therapy and non-pharmacological interventions, followed by conservative treatment with non-steroidal anti-inflammatory drugs, then glucocorticoid steroids and, finally, administration of a conventional disease-modifying antirheumatic drug (DMARD). This concept is now inverted. Intensive intervention, initiated earlier, with conventional and biological DMARDs is increasingly recommended ...
Follow-up there was a time categorized on the person-day foundation intended for treatment coverage. Several teams of medicines appealing have been the following: anti-tumor necrosis factor (TNF) biologics (adalimumab, etanercept, infliximab, certolizumab, as well as golimumab), non-TNF biologics (abatacept along with rituximab), nonbiologic immunosuppressive drugs (or perhaps disease-modifying antirheumatic drug treatments [DMARDs]) (methotrexate, hydroxycholoroquine, sulfasalazine, azathioprine, leflunomide, cyclosporine, and 6-mercaptopurine), and also oral glucocorticoids. Experience of biologics and also nonbiologic DMARDs was firm depending on prescribed time along with days of supply and, with regard to infusions, the particular encouraged dosing intervals. For example, the patient who gotten an infliximab infusion was deemed exposed to infliximab for the next Fifty six days and nights from the infusion day. As the exact every day dose associated with mouth glucocorticoids is actually ...
The goal of this research was to compare the demographics, clinical characteristics and treatment patterns for newly diagnosed multiple sclerosis (MS) patients in a commercial managed care population who received disease-modifying drug (DMD) therapy
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Objective To determine whether intensive combinations of synthetic disease modifying drugs can achieve similar clinical benefits at lower costs to high cost biologics such as tumour necrosis factor inhibitors in patients with active rheumatoid arthritis resistant to initial methotrexate and other synthetic disease modifying drugs.. Design Open label pragmatic randomised multicentre two arm non-inferiority trial over 12 months.. Setting 24 rheumatology clinics in England.. Participants Patients with rheumatoid arthritis who were eligible for treatment with tumour necrosis factor inhibitors according to current English guidance were randomised to either the tumour necrosis factor inhibitor strategy or the combined disease modifying drug strategy.. Interventions Biologic strategy: start tumour necrosis factor inhibitor; second biologic in six month for non-responders. Alternative strategy: start combination of disease modifying drugs; start tumour necrosis factor inhibitors after six months in ...
Abatacept(Orencia) generic is a synthetic protein, prescribed for adult with moderate to severe rheumatoid arthritis including patients who have not responded to DMARDs (disease-modifying anti-rheumatic drugs), and juvenile idiopathic arthritis. It blocks the activity of T-cells, which causes swelling and joint damage in people with arthritis condition.
Background: Clinically relevant drug-drug interactions (DDIs) must be recognized in a timely manner and managed appropriately to prevent adverse drug reactions or therapeutic failure. Because the evidence for most DDIs is based on case reports or poorly documented clinical information, there is a need for better assessment of their clinical relevance. Objective: This study evaluates the interdisciplinary agreement between rheumatologists and clinical (hospital) pharmacists in assessing the clinical relevance of DDIs with disease-modifying antirheumatic drugs (DMARDs) and non-DMARD medications. Methods: Potential DDIs were identified from the medical literature using MEDLINE and EMBASE for the years 1968-2009. The following search terms were used for the key word, title, and abstract sections of the publications: interaction(s), DMARD, disease-modifying antirheumatic drug(s), antirheumatic, rheumatology, rheumatoid arthritis, and the names of the individual DMARDs of interest (abatacept, ...
TY - JOUR. T1 - A longitudinal analysis of prevalence of sustained remission and low disease activity in rheumatoid arthritis patients treated with anti-tumour necrosis factor: an analysis of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. AU - Hamann, Philip D H. AU - Shaddick, Gavin. AU - McHugh, Neil. AU - Hyrich, Kimme. AU - Pauling, John D. PY - 2018/4/30. Y1 - 2018/4/30. N2 - Background: Attainment of remission or low disease activity (LDA) are recommended targets for rheumatoid arthritis (RA) treatment, and associated with improved functional and radiographic long-term outcomes. However, evidence reporting the prevalence of sustained remission/LDA is sparse. This study examines how often sustained remission/LDA occurs, and how this outcome has changed between 2001 and 2013 in patients with RA treated with anti-tumour necrosis factor (TNF) using data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA).Methods: ...
TY - JOUR. T1 - Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. AU - Iervolino, Salvatore. AU - Di Minno, Matteo Nicola Dario. AU - Peluso, Rosario. AU - Lofrano, Mariana. AU - Russolillo, Anna. AU - Di Minno, Giovanni. AU - Scarpa, Raffaele. PY - 2012/3. Y1 - 2012/3. N2 - Objective. To identify predictors of early minimal disease activity in patients with psoriatic arthritis (PsA) receiving tumor necrosis factor-&αλπηα; (TNF-α) antagonists. Methods. In total 146 consecutive patients with PsA eligible for anti-TNF- &αλπηα; therapy were enrolled. At baseline (T0) information about age, sex, PsA subset, disease duration, comorbidities, and treatments was collected. All subjects were tested for metabolic syndrome (MetS) and/or liver steatosis. A clinical and laboratory evaluation was performed at T0 and at 3 months (T3). Changes in all these variables were compared in subjects achieving minimal disease ...
Swedish researchers analyzed data from 6,366 rheumatoid arthritis patients who started anti-TNF therapy with infliximab (Remicade), adalimumab (Humira) or etanercept (Enbrel) between January 1999 and July 2006. The study participants were compared with other groups of rheumatoid arthritis patients, including 61,160 not taking medications, 4,015 taking methotrexate (the gold standard of treatment) and 4,105 taking combinations of disease-modifying anti-rheumatic drugs (other than TNF blockers).. According to the study authors, 240 first cancers were diagnosed during follow-up among patients who had no history of cancer when they began anti-TNF treatment. Compared to rheumatoid arthritis patients who didnt take anti-TNF drugs or those with no history of cancer, the relative cancer risk of anti-TNF therapy was 1.00 and remained unchanged for those taking immunosuppressant drugs for up to six years, the researchers found.. Our research indicates the overall cancer risk is the same for rheumatoid ...
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from a long-term (52-week) phase III trial of OTEZLA, the Companys oral, selective inhibitor of phosphodiesterase 4 (PDE4), in psoriatic arthritis patients who have not had prior treatment with systemic or biologic disease-modifying antirheumatic drugs (DMARDs). The data were presented at the European League Against Rheumatism Annual Congress (EULAR 2014) in Paris, France.. Physicians need a variety of options to treat psoriatic arthritis, as treatment is highly individualized and some patients may not be appropriate candidates for biologics or certain systemic therapies, said Alvin Wells, M.D., Ph.D., director, Rheumatology and Immunology Center, Franklin, MN. These efficacy and safety results suggest that OTEZLA monotherapy has the potential to be used for adults with active psoriatic arthritis in the first-line setting, prior to the initiation of DMARDtherapy, and possibly ...
In part 1 of A Paradigm Shift in Rheumatoid Arthritis Disease Activity, we considered some reasons why better ways of considering RA disease activity are n
In a final appraisal determination, NICE has recommended the biological disease-modifying antirheumatic drug (DMARD) sarilumab (Kevzara) for routine NHS use in the treatment of certain patients with rheumatoid arthritis.. Sarilumab, in combination with methotrexate, is recommended as an option for the treatment of severe active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional DMARDs. Severe disease is defined as a disease activity score (DAS28) of more than 5.1. Sarilumab is also recommended with methotrexate in adults with severe active disease who have responded inadequately to, or who cannot take, other DMARDs, including at least one biological DMARD, and who cannot take rituximab.. NICE adds that sarilumab can be used as monotherapy in patients who cannot take methotrexate because of a contraindication or intolerance. Treatment should be continued only if there is at least a moderate response, as measured using ...
Objective: We aimed to mine the data in the Electronic Medical Record to automatically discover patients Rheumatoid Arthritis disease activity at discrete rheumatology clinic visits. We cast the problem as a document classification task where the feature space includes concepts from the clinical narrative and lab values as stored in the Electronic Medical Record. Materials and Methods The Training Set consisted of 2792 clinical notes and associated lab values. Test Set 1 included 1749 clinical notes and associated lab values. Test Set 2 included 344 clinical notes for which there were no associated lab values. The Apache clinical Text Analysis and Knowledge Extraction System was used to analyze the text and transform it into informative features to be combined with relevant lab values. Results: Experiments over a range of machine learning algorithms and features were conducted. The best performing combination was linear kernel Support Vector Machines with Unified Medical Language System Concept ...
Background/Purpose: The impact of gender on tumor necrosis factor inhibitors (TNFi) effectiveness has been poorly studied in Psoriatic Arthritis (PsA) patients. The objective of this work was to study gender differences in persistence and response to a first TNFi in PsA patients.. Methods: PsA patients prospectively followed at the Rheumatic Diseases Portuguese Registry (Reuma.pt), treated with a first TNFi, between 2001 and 2017 were included. Drug retention was assessed by Kaplan-Meier survival analysis and Cox models adjusted for the year of starting a TNFi. Response rates measured by European League Against Rheumatism (EULAR) response, Disease Activity Index for Psoriatic Arthritis (DAPSA) remission, Minimal Disease Activity (MDA) and Ankylosing Spondylitis Disease Activity Score (ASDAS) response, applying the LUNDEX method, were compared between genders. Baseline predictors of discontinuation and response were identified (Cox and multivariable multinomial/logistic regression ...
Nature Reviews Rheumatology, Published online: 17 February 2020; doi:10.1038/s41584-020-0394-4Publisher Correction: Immunological adaptations in pregnancy that modulate rheumatoid arthritis disease activity...
Automatic Prediction of Rheumatoid Arthritis Disease Activity from the Electronic Medical Records The Harvard community has made this article openly available. Please share how this access benefits you.
Research has shown a positive correlation between bariatric surgery-associated weight loss and decreased rheumatoid arthritis disease activity.
TY - JOUR. T1 - Cyclosporine and methotrexate for severe rheumatoid arthritis. AU - Schlesinger, Naomi. AU - Huppert, Arthur. AU - Hoch, Susan. AU - Malleson, Peter. AU - Steinberg, Alfred D.. AU - Rosh, Joel. AU - Birnbaum, Audrey H.. AU - Van de Rijn, Matthijs. AU - Kamel, Onsi W.. AU - Storb, Rainer. AU - Thomas, E. Donnall. AU - Tugwell, Peter. AU - Yocum, David. AU - Pincus, Theodore. AU - Wells, George. PY - 1995/12/7. Y1 - 1995/12/7. N2 - To the Editor: Tugwell et al. (July 20 issue)1 found that patients with severe rheumatoid arthritis and only partial responses to methotrexate had clinically important improvement after combination therapy with cyclosporine and methotrexate. We are concerned about the manner in which the cyclosporine doses were adjusted. No mention of the patients serum cyclosporine levels was made. Determination of serum cyclosporine levels might have allowed a better understanding of the results with respect to therapeutic serum ranges of this medication. The ...
Rheumatoid arthritis (RA) is the most common inflammatory form of arthritis. It is a systemic autoimmune driven process that affects more than 2 million Americans.. While disease-modifying anti-rheumatic drugs (DMARDS) were our stalwarts through the 1980′s and early 1990′s, biologic drugs, specifically TNF inhibitors, have changed our whole way of looking at the treatment of rheumatoid arthritis.. Using these drugs in combination with DMARDS, it has been possible to induce remission in many patients with RA.. TNF inhibitors block the effects of tumor necrosis factor (TNF), a protein messenger that drives the autoimmune process that causes the destructive potential of RA.. There are five TNF inhibitors that have been approved by the FDA. The first is Enbrel. This is a fusion protein with a receptor that binds to circulating TNF in the blood. By acting like a sponge it reduces the signs and symptoms of RA. It is generally best when used in combination with methotrexate. The drug is given by ...
TY - JOUR. T1 - Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors. T2 - a meta-analysis. AU - Ungprasert, Patompong. AU - Thongprayoon, Charat. AU - Davis, John Manley III. PY - 2016/2/6. Y1 - 2016/2/6. N2 - Significant portion of patients with psoriatic arthritis (PsA) could not tolerate or do not have a satisfactory response to either non-steroidal anti-inflammatory drugs (NSAIDs), non-biologic disease-modifying anti-rheumatic drugs (DMARDs), or even TNF inhibitors. Non-TNF inhibitor biologic agents have emerged as second-line therapy in such situation. However, the comparative efficacy of these agents remains unknown as head-to-head randomized controlled trials (RCTs) are not available. RCTs examining the efficacy of non-TNF inhibitor biologic agents in patients with PsA who experienced inadequate response or intolerance of TNF inhibitors were identified. If more than one ...
BACKGROUND: The recent outbreak of COVID-19 has raised concerns in the rheumatology community about the management of immunosuppressed patients diagnosed with inflammatory rheumatic diseases. It is not clear whether the use of biological agents may suppose a risk or protection against SARS-CoV-2 infection; however, it has been suggested that severe respiratory forms of COVID-19 occur as a result of exacerbated inflammation status and cytokine production. This prompted the use of interleukin 6 (IL-6) (tocilizumab and sarilumab) and IL-1 inhibitors (anakinra) in severe COVID-19 disease and more recently JAK1/2 inhibitor (baricitinib). Therefore, patients with rheumatic diseases provide a great opportunity to learn about the use of biological agents as protective drugs against SARS-CoV-2. OBJECTIVES: To estimate COVID-19 infection rate in patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) for inflammatory rheumatic diseases (RMD), determine the influence of biological ...
The European Commission (EC) has approved Pfizers Xeljanz (tofacitinib citrate) oral tablets to treat moderate-to-severe active rheumatoid arthritis (RA) in adult patients in the European Union (EU).. The 5mg twice-daily (BID) tablets have been approved in combination with methotrexate (MTX) for patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).. Xeljanz belongs to a new class of therapies called Janus kinase (JAK) inhibitors, and can be given as monotherapy in case of intolerance to MTX, or when treatment with MTX is otherwise inappropriate.. Pfizer Innovative Health Inflammation & Immunology regional president Angela Lukin said: With a heritage of more than 60 years of providing rheumatoid arthritis treatment options, Pfizer has been a leader in helping to improve the lives of people with inflammatory conditions.. The approval of Xeljanz in Europe demonstrates Pfizers ongoing commitment to developing medicines ...
A working group convened by the American College of Rheumatology (ACR) has evaluated more than 60 disease activity measures for rheumatoid arthritis (RA). The group narrowed the number of RA disease activity measures and ...
Anti-tumor necrosis factor (anti-TNF) therapies are highly effective in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but a significant number of patients exhibit only a partial or no therapeutic response. Inflammation alters local and systemic metabolism, and TNF plays a role in this. We undertook this study to determine if the patients metabolic fingerprint prior to therapy could predict responses to anti-TNF agents.Urine was collected from 16 RA patients and 20 PsA patients before and during therapy with infliximab or etanercept. Urine metabolic profiles were assessed using nuclear magnetic resonance spectroscopy. Discriminating metabolites were identified, and the relationship between metabolic profiles and clinical outcomes was assessed.Baseline urine metabolic profiles discriminated between RA patients who did or did not have a good response to anti-TNF therapy according to European League Against Rheumatism criteria, with a sensitivity of 88.9% and a specificity of 85.7%, with several
Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis Alberto Migliore,1 Emanuele Bizzi,1 Colin Gerard Egan,2 Mauro Bernardi,3 Lea Petrella4 1Rheumatology Unit, San Pietro Fatebenefratelli Hospital, Rome, 2Primula Multimedia SRL, Pisa, 3Department of Statistical Sciences, University of Padova, Padova, 4MEMOTEF Department, Sapienza University of Rome, Rome, Italy Background: Biological agents provide an important therapeutic alternative for rheumatoid arthritis patients refractory to conventional disease-modifying antirheumatic drugs. Few head-to-head comparative trials are available.Purpose: The aim of this meta-analysis was to compare the relative efficacy of different biologic agents indicated for use as monotherapy in rheumatoid arthritis.Methods: A systemic literature search was performed on electronic databases to identify articles reporting double-blind randomized controlled trials investigating the efficacy of biologic
INTRODUCTION: The introduction of biological disease-modifying antirheumatic drugs (bDMARDs) has improved the treatment of inflammatory rheumatic diseases dramatically. However, bDMARD treatment failure occurs in 30%-40% of patients due to lack of effect or adverse events, and the tools to predict treatment outcomes in individual patients are currently limited. The objective of the present study is to identify diagnostic, prognostic and predictive biomarkers, which can be used to (1) diagnose inflammatory rheumatic diseases early in the disease course with high sensitivity and specificity, (2) improve prognostication or (3) predict and monitor treatment effectiveness and tolerability for the individual patient ...
Find the best rheumatoid arthritis treatment in Gurgaon. Get guidance from medical experts to select heumatoid arthritis treatment in Gurgaon.
Actemra/RoActemra is the only approved anti-IL-6 receptor biologic, available in both intravenous (IV) and subcutaneous (SC) formulations, for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA). Actemra/RoActemra can be used alone or with methotrexate (MTX) in adults who are intolerant to, or have failed to respond to other anti-rheumatic medications. In the most recent update to the European League Against Rheumatism (EULAR) RA management guidelines, Actemra/RoActemra is highlighted as the only biologic that has been repeatedly demonstrated to be superior as a monotherapy over MTX or other conventional disease-modifying antirheumatic drugs (DMARDs). The extensive Actemra/RoActemra RA IV clinical development program included five Phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries. The Actemra/RoActemra RA SC clinical development program included two Phase III clinical studies and enrolled more than 1,800 people with RA in ...
Actemra / RoActemra is the first approved anti-IL-6 receptor biologic available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA). Actemra / RoActemra can be used alone or with methotrexate (MTX) in adults who are intolerant to, or have failed to respond to, other anti-rheumatic medications. The most recent European League Against Rheumatism (EULAR) RA management guidelines state that Actemra / RoActemra monotherapy has better efficacy, in regard to signs and symptoms, physical function and joint damage, over MTX or other conventional disease-modifying antirheumatic drugs (DMARDs). The extensive Actemra / RoActemra RA IV clinical development programme included five phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries. The Actemra / RoActemra RA SC clinical development programme included two phase III clinical studies and enrolled more than 1,800 people with RA ...
Natural cures for Rheumatoid Arthritis: Rheumatoid Arthritis Treatment At Kolkata. Rheumatoid Arthritis Aid, Treatments for Rheumatoid Arthritis .
Seattle, Wa (PRWEB) September 02, 2013 -- Paddison Program For Rheumatoid Arthritis is a high-effective rheumatoid arthritis treatment that provides people
2017 Juvenile Rheumatoid Arthritis Treatment Natural Causes Effective All Natural Treatments For Arthritis Dr Axe and Osalteoarthritis - draxe.com. All the tendons and suspensory ligaments which will develop the mutual with each other deteriorate and stretch. Steadily, the mutual will lose it has the figure and alignment. Healthcare doctors are not familiar with precisely what will begin this, however a genetic ingredient seems likely. Even when your passed dow genes wont really induce rheumatoid arthritis symptoms, they will make you weaker in order to external components, such as fungi having confident germs and micro organism, which will trigger the disease.. ...
Background/Purpose:. Filgotinib (FIL) is an orally administered, selective Janus Kinase 1 (JAK1) inhibitor in development for inflammatory diseases. The efficacy and safety of FIL was evaluated in patients (pts) with active psoriatic arthritis (PsA) who had an inadequate response (IR) to conventional disease-modifying anti-rheumatic drugs (cDMARDs). Methods:. This was a 16-week, randomized, placebo (PBO)-controlled, double-blind, multicenter, Phase 2 study. Eligible pts had PsA (meeting CASPAR criteria) for ≥12 weeks, active arthritis (≥5 tender and ≥5 swollen joints), prior/current plaque psoriasis, IR to ≥1 cDMARD and prior exposure to ≤ 1 TNF-inhibitor. Pts were allowed to continue cDMARDs during the trial. Pts were randomized 1:1 to FIL 200mg once daily (qd) or PBO. Disease activity was assessed at screening, baseline and weeks 1, 2, 4, 8, 12 and 16. The primary endpoint was the percentage of pts achieving a 20% American College of Rheumatology (ACR20) response at week 16. ...
Switching biologic disease-modifying anti-rheumatic drug (bDMARD) therapy after failure of a first bDMARD for the treatment of psoriatic arthritis (PsA) can be effective, according to a review of the literature and PsA consensus treatment recommendations.. Investigators led by Joseph F. Merola, MD, from Harvard Medical School, Boston, conducted a literature review to determine the efficacy and safety related to switching between bDMARDs in the treatment of PsA, and they evaluated PsA treatment recommendations from national rheumatology societies to identify consensus guidelines on switching.. They noted that data from the clinical literature on switching bDMARD therapies in PsA are limited, with most studies being observational or retrospective. Treatment responses have been decreased when switching from one tumor necrosis factor inhibitor (TNFi) to a second or third TNFi, and the patient characteristics that predict efficacy after switching arent clear, they wrote online in Seminars in ...
Purpose: Rituximab (RTX) improves signs and symptoms and slows joint damage progression in patients (pts) with rheumatoid arthritis (RA). This study explored the safety of RTX in combination with a TNF inhibitor (etanercept or adalimumab) and MTX in pts with active RA. Methods: Pts with active RA (swollen joint count ≥5 and tender joint count ≥5) receiving a stable dose of etanercept (50 mg qw) or adalimumab (40 mg q2w) and methotrexate (10-25 mg qw) for at least 12 weeks were eligible. Pts were randomized 2:1 and treated with 500 mg RTX or placebo (PLA) on Days 1 and 15. After Wk 24, eligible pts could enter open-label treatment with RTX. The primary endpoint was the proportion of pts who experience ≥1 serious infection through Wk 24. Secondary endpoints evaluated additional safety and efficacy parameters. Results: Fifty-one pts received at least one dose of study treatment (33 RTX, 18 PLA). The concomitant TNF inhibitors were balanced between treatment groups: etanercept (76% vs 78%) and ...
Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA).. The announcement comes after the U.S. Food and Drug Administration approving the therapy in May. The agency authorized Kevzara for adults with RA who failed to responded to, or were unable to tolerate, disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX).. Canada approved Kevzara in January, and the European Union is expected to decide on the drugs Marketing Authorization Application in coming months.. Kevzara is an interleukin-6 receptor antagonist that can be used alone or in combination with MTX or other DMARDs. It is administrated by injection. The recommended dose is 200 mg once every two weeks, but it can be reduced to 150 mg if routine blood tests reveal abnormalities.. Diplomat is the nations largest independent provider of specialty pharmacy services, offering medication management programs for people with complex chronic ...
Comprehensive video overview that covers, transcript, educational quiz, printable action plan, symptoms, causes and treatment options for (Rheumatoid Arthritis Treatment at HealthChoicesFirst.com)
Natural rheumatoid arthritis treatment options like omega 3 fatty acids (plants and coldwater fish) can substantially reduce arthritis pain and other symptoms.
While monoclonal antibodies against tumor necrosis factor-α (TNFα) are effective in treating Crohns disease (CD), approximately one-third
... is an antirheumatic agent. Iversen M, Munck J, Schourup K (1953). "On the toxicity of 3-hydroxy-2- ...
It is an antirheumatic agent in veterinary medicine. It has attracted interest as an anticancer agent. Aminopropionitrile is ...
... is an antirheumatic agent developed from tiopronin. Activity is mediated by the two thiol groups that the molecule ...
... is a gold salt used as an antirheumatic agent. Perrier P, Raffoux C, Thomas P, Tamisier JN, Busson M, Gaucher A, ... levamisole and D-penicillamine as first choice slow-acting antirheumatic drugs in rheumatoid arthritis--a long-term follow-up ...
A61P29/00 Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti- ...
The main uses of mepacrine are as an antiprotozoal, antirheumatic and an intrapleural sclerosing agent. Antiprotozoal use ... Agents Chemother. 55 (5): 1827-1830. doi:10.1128/aac.01296-10. PMC 3088196. PMID 21383088. Canete R, Escobedo AA, Gonzalez ME, ... As an intrapleural sclerosing agent, it is used as pneumothorax prophylaxis in patients at high risk of recurrence, e.g., ... "quinacrine" at Dorland's Medical Dictionary Doh-Ura K, Iwaki T, Caughey B (May 2000). "Lysosomotropic Agents and Cysteine ...
... is a gold salt classified by the World Health Organization as an antirheumatic agent. It has the brand name Ridaura. ... the protozoan agent of human amebiasis. Assays of thioredoxin reductase and transcriptional profiling suggest that the effect ...
... may have anti-inflammatory properties and reduce damage from arthritis.Some cucurbitacins can be made anti-rheumatic agent. " ...
"Studies on antirheumatic agents: 3-benzoylpropionic acid derivatives", Chem. Pharm. Bull., 36 (6), pp. 2050-2060, doi:10.1248/ ...
The term is often used in contrast to nonsteroidal anti-inflammatory drugs (which refers to agents that treat the inflammation ... "disease-modifying antirheumatic drug" at Dorland's Medical Dictionary "Disease modifying antirheumatic drugs (DMARDs)". " ... Disease-modifying antirheumatic drugs (DMARDs) comprise a category of otherwise unrelated drugs defined by their use in ... Nandi P, Kingsley GH, Scott DL (May 2008). "Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid ...
975 Poisoning by agents primarily acting on the smooth and skeletal muscles and respiratory system 976 Poisoning by agents ... and antirheumatics 966 Poisoning by anticonvulsants and anti-Parkinsonism drugs 967 Poisoning by sedatives and hypnotics 968 ... the autonomic nervous system 972 Poisoning by agents primarily affecting the cardiovascular system 973 Poisoning by agents ... 962 Poisoning by hormones and synthetic substitutes 963 Poisoning by primarily systemic agents 964 Poisoning by agents ...
Prognosis of acquired immune deficiencies depends on avoiding or treating the causative agent or condition (like AIDS). ... disease-modifying antirheumatic drugs, immunosuppressive drugs after organ transplants, glucocorticoids) and environmental ... can result from various immunosuppressive agents, for example, malnutrition, aging, particular medications (e.g., chemotherapy ...
... adverse effects in therapeutic use E933 Primarily systemic agents causing adverse effects in therapeutic use E934 Agents ... at Unspecified place E849.0 Place of occurrence at home E850 Accidental poisoning by analgesics antipyretics and antirheumatics ... use E942 Agents primarily affecting the cardiovascular system causing adverse effects in therapeutic use E943 Agents primarily ... in therapeutic use E944 Water mineral and uric acid metabolism drugs causing adverse effects in therapeutic use E945 Agents ...
The biologic agent rituximab (anti-B cell therapy) is now licensed for use in refractory rheumatoid arthritis.Physiotherapy is ... disease-modifying antirheumatic drugs), monoclonal antibodies, such as infliximab and adalimumab, the TNF inhibitor etanercept ...
Where this condition has been correctly diagnosed, various anti-rheumatic drugs as well as colchicine may be trialled to find ... achieved using intra-articular agents (chemical or radioactive) can provide good results, with efficacy reported for at least 1 ... Low-dose colchicine (and some other 'anti-rheumatic' therapies e.g. hydroxychloroquine) have been used with some success. (Use ...
It is used as a chelating agent: In Wilson's disease, a rare genetic disorder of copper metabolism, penicillamine treatment ... Penicillamine can be used as a disease-modifying antirheumatic drug (DMARD) to treat severe active rheumatoid arthritis in ... although it is rarely used today due to availability of TNF inhibitors and other agents, such as tocilizumab and tofacitinib. ...
It is considered a promising agent as it inhibits JAK1 selectively, similar to already marketed upadacitinib.[medical citation ... modifying anti‑rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX). ... Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment (FINCH 2)" at ... on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic ...
Prognosis of acquired immune deficiencies depends on avoiding or treating the causative agent or condition (like AIDS). ... disease-modifying antirheumatic drugs, immunosuppressive drugs after organ transplants, glucocorticoids) and environmental ... Secondary immunodeficiencies, also known as acquired immunodeficiencies, can result from various immunosuppressive agents, for ...
... antirheumatic agents MeSH D27.505.954.329.030 - anti-inflammatory agents, non-steroidal MeSH D27.505.954.329.337 - gout ... antiviral agents MeSH D27.505.954.122.388.077 - anti-retroviral agents MeSH D27.505.954.122.388.077.088 - anti-hiv agents MeSH ... tocolytic agents MeSH D27.505.954.016 - anti-allergic agents MeSH D27.505.954.122 - anti-infective agents MeSH D27.505.954.122. ... tranquilizing agents MeSH D27.505.696.277.950.015 - anti-anxiety agents MeSH D27.505.696.277.950.025 - antimanic agents MeSH ...
Like several other gold compounds, this species is used as an antirheumatic. The first placebo-controlled trial was probably ... doi:10.1016/S1386-1425(97)83024-7. Shaw III CF (September 1999). "Gold-based therapeutic agents". Chemical Reviews. 99 (9): ...
He carried out research into the effect of salicin, an extract from willow bark and a known anti-rheumatic treatment. This work ... Stewart, William K.; Fleming, L. W. (1 October 1987). "Perthshire Pioneer of Anti-Inflammatory Agents". Scottish Medical ...
Twohig KJ, Matthay RA (March 1990). "Pulmonary effects of cytotoxic agents other than bleomycin". Clinics in Chest Medicine. 11 ... "Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis". The Journal of Rheumatology. 18 (2): 188- ... The main use of cyclophosphamide is with other chemotherapy agents in the treatment of lymphomas, some forms of brain cancer, ... Like other alkylating agents, cyclophosphamide is teratogenic and contraindicated in pregnant women (pregnancy category D) ...
June 1995). "A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis ... "Rationally designed multitarget agents against inflammation and pain". Current Medicinal Chemistry. 20 (13): 1783-99. doi: ...
In 1959 it became the eighth cytotoxic anticancer agent to be approved by the FDA. The abbreviation CP is common, although ... it remains an important treatment for life-threatening autoimmune diseases where disease-modifying antirheumatic drugs (DMARDs ... The main use of cyclophosphamide is with other chemotherapy agents in the treatment of lymphomas, some forms of brain cancer, ... Like other alkylating agents, cyclophosphamide is teratogenic and contraindicated in pregnant women (pregnancy category D) ...
Biological agents should generally only be used if methotrexate and other conventional agents are not effective after a trial ... Disease-modifying antirheumatic drugs (DMARDs), such as hydroxychloroquine and methotrexate, may be used to try to slow the ... The most commonly used agent is methotrexate with other frequently used agents including sulfasalazine and leflunomide. ... No infectious agent has been consistently linked with RA and there is no evidence of disease clustering to indicate its ...
People who have previously been treated with an alkylating agent may have an excessive risk of cancers if treated with ... Being a disease-modifying antirheumatic drug (DMARD), azathioprine has been used for the management of the signs and symptoms ... It is also an important therapy and steroid-sparing agent for inflammatory bowel disease (such as Crohn's disease and ... agent. Azathioprine is also used to maintain remission in people who have granulomatosis with polyangiitis. It can be very ...
Seed is rubefacient, stimulant, purgative, and antidote for snakebite and its oil is antirheumatic. Leaf is antiasthmatic and ... Potential anticancer agents. VIII. Constituents of Baliospermum montanum (Euphorbiaceae). Planta med., 33:128.. ...
As a topical agent and as a beta-hydroxy acid (and unlike alpha-hydroxy acids), salicylic acid is capable of penetrating and ... Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory ...
ISBN 978-0-9805790-9-3. Berners-Price, SJ; Filipovska, A (September 2011). "Gold compounds as therapeutic agents for human ... is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Along with an orally-administered gold salt, ...
A contrast agent is injected into the parotid duct, which opens from the cheek into the vestibule of the mouth opposite the ... Also, disease-modifying antirheumatic drugs such as methotrexate may be helpful. Hydroxychloroquine (Plaquenil) is another ... Epstein-Barr virus, hepatitis C, and human T-cell leukemia virus-1 are among the most studied infectious agents in Sjögren's ... Although a number of infectious, exogenous agents have been implicated in the pathogenesis of Sjögren's syndrome, such as ...
After the identification of B. burgdorferi as the causative agent of Lyme disease, antibiotics were selected for testing, ... disease-modifying antirheumatic drugs (DMARDs), or arthroscopic synovectomy.[30] Physical therapy is recommended for adults ... Former Ocean County Agricultural Agent and George C. Hamilton, PhD, Extension Specialist in Pest Management, March 2005. ... "Ticks and biting insects infected with the etiologic agent of Lyme disease, Borrelia burgdorferi". Journal of Clinical ...
Cannabinoids are used in patients with cachexia, cytotoxic nausea, and vomiting, or who are unresponsive to other agents. These ...
Similarly, one might argue that the class of disease-modifying anti-rheumatic drugs (DMARD) is composed by one element (" ... not all triglyceride lowering agents are PPAR agonists, and not all drugs that are used to treat atherosclerosis are ... "disease-modifying") that albeit vaguely designates a mechanism of action, and one element ("anti-rheumatic drug") that ...
Psychotropic agents[edit]. Other psychotropic analgesic agents include ketamine (an NMDA receptor antagonist), clonidine and ... Unselective agents Aceclofenac. Comes in betadex salt and free acid forms; practically insoluble in water, soluble in many ... Other agents directly potentiate the effects of analgesics, such as using hydroxyzine, promethazine, carisoprodol, or ... When choosing analgesics, the severity and response to other medication determines the choice of agent; the World Health ...
It may be used as a nasal/sinus decongestant, as a stimulant,[119] or as a wakefulness-promoting agent.[120] ... Tashkin, D. P. (1 March 2001). "Airway effects of marijuana, cocaine, and other inhaled illicit agents". Current Opinion in ... and anorectic agent.[112] It is commonly used in prescription and over-the-counter cough and cold preparations. In veterinary ... "Phenylisopropylamine stimulants: amphetamine-related agents". In Lemke TL, Williams DA, Roche VF, Zito W (eds.). Foye's ...
Available agents[edit]. Main article: List of antineoplastic agents. There is an extensive list of antineoplastic agents. ... Alkylating agents[edit]. Main article: Alkylating antineoplastic agent. Alkylating agents are the oldest group of ... Siddik ZH (2005). Mechanisms of Action of Cancer Chemotherapeutic Agents: DNA-Interactive Alkylating Agents and Antitumour ... Anti-microtubule agents[edit]. Vinca alkaloids prevent the assembly of microtubules, whereas taxanes prevent their disassembly ...
List of agents[edit]. Adrenaline releasing agents[edit]. Main article: Norepinephrine releasing agent ... 3 List of agents *3.1 Adrenaline releasing agents *3.1.1 Common or widely marketed ... since these agents lose effectiveness after a few days. ... Antirheumatics. *Corticosteroids. *Muscle relaxants. * ...
It may be used alone or in combination with disease-modifying antirheumatic drugs (DMARD).[14] It has also been shown to have ... Similar agents[edit]. *Certolizumab pegol. *Etanercept. *Golimumab. *Infliximab. References[edit]. *^ a b c .mw-parser-output ... Adalimumab is a disease-modifying antirheumatic drug and monoclonal antibody that works by inactivating tumor necrosis factor- ...
"Dermatotherapeutic Agents". Ullmann's Encyclopedia of Industrial Chemistry (7th ed.). 2007. doi:10.1002/14356007.a08_301.pub2. ... Kyriakidis I, Tragiannidis A, Munchen S, Groll AH (February 2017). "Clinical hepatotoxicity associated with antifungal agents ... "The cost effectiveness of testing for onychomycosis versus empiric treatment of onychodystrophies with oral antifungal agents ... "Current and emerging azole antifungal agents". Clinical Microbiology Reviews. 12 (1): 40-79. PMC 88906. PMID 9880474 ...
Within the class of medications, there is no clear evidence that one agent works better than another.[1][2] ... In British Columbia, Canada the cost of the PPIs varies significantly from 0.20 CAD to 2.38 CAD per dose while all agents in ... The cost between different agents varies significantly.[1] ... Antirheumatics. *Corticosteroids. *Muscle relaxants. * ...
The term "calcium-sparing diuretic" is sometimes used to identify agents that result in a relatively low rate of excretion of ... Alternatively, an antidiuretic, such as vasopressin (antidiuretic hormone), is an agent or drug which reduces the excretion of ... Diuretics increase the urine volume and dilute doping agents and their metabolites. Another use is to rapidly lose weight to ... "The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: pharmacology, toxicology and ...
Reducing agent (antioxidant), e.g. if epinephrine is used, then sodium metabisulfite is used as a reducing agent ... LA drugs are also often combined with other agents such as opioids for synergistic analgesic action.[1] Low doses of LA drugs ... This can be a factor in choosing an agent in patients with liver failure,[56] although since cholinesterases are produced in ... Even with proper administration, it is inevitable for some diffusion of agent into the body from the site of application due to ...
antifungal, alkalinizing agents, quinolones, antibiotics, cholinergics, anticholinergics, antispasmodics, 5-alpha reductase ... In the inter-war period, the first anti-bacterial agents such as the sulpha antibiotics were developed. The Second World War ... These were drugs that worked chiefly as anti-anxiety agents and muscle relaxants. The first benzodiazepine was Librium. Three ... HMG-CoA reductase inhibitors (statins) for lowering LDL cholesterol inhibitors: hypolipidaemic agents. ...
Alkylating agents[edit]. The alkylating agents used in immunotherapy are nitrogen mustards (cyclophosphamide), nitrosoureas, ... Small biological agents[edit]. Fingolimod is a new synthetic immunosuppressant, currently in phase 3 of clinical trials. It ... Immunosuppressive drugs, also known as immunosuppressive agents, immunosuppressants and antirejection medications are drugs ... Immunosuppressive+Agents at the US National Library of Medicine Medical Subject Headings (MeSH) ...
Alkylating agents[edit]. The alkylating agents used in immunotherapy are nitrogen mustards (cyclophosphamide), nitrosoureas, ... Small biological agents[edit]. Fingolimod is a new synthetic immunosuppressant, currently in phase 3 of clinical trials. It ... Immunosuppressive drugs or immunosuppressive agents or antirejection medications are drugs that inhibit or prevent activity of ... Immunosuppressive+Agents at the US National Library of Medicine Medical Subject Headings (MeSH) ...
Agents Chemother. 12 (5): 642-6. doi:10.1128/AAC.12.5.642. PMC 429991 . PMID 303498.. ... Also indirect D2 agonists, such as dopamine reuptake inhibitors (cocaine, methylphenidate), releasing agents (amphetamine, ... Virtue, RW; Alanis, JM; Mori, M; Lafargue, RT; Vogel, JH; Metcalf, DR (1967). "An anaesthetic agent: 2-orthochlorophenyl, 2- ... a PCP-receptor-acylating agent". Synapse. 1 (5): 497-504. doi:10.1002/syn.890010514. PMID 2850626.. ...
"Pharmacologic Agents That Promote Airway Clearance in Hospitalized Subjects: A Systematic Review" (PDF). Respiratory Care. 60 ...
Disease-modifying antirheumatic drug (DMARD)[5]. Other systems of classification[edit]. Other systems of drug classification ... not all triglyceride lowering agents are PPAR agonists, and not all drugs that are used to treat atherosclerosis are ... Similarly, one might argue that the class of disease-modifying anti-rheumatic drugs (DMARD) is composed by one element (" ... "disease-modifying") that albeit vaguely designates a mechanism of action, and one element ("anti-rheumatic drug") that ...
Thyroid hormones/Antithyroid agents. Infections and. infestations (J, P, QI). *Antimicrobials: Antibacterials ( ...
LDL-lowering potency varies between agents. Cerivastatin is the most potent, (withdrawn from the market in August, 2001 due to ... Thurnher M, Nussbaumer O, Gruenbacher G (July 2012). "Novel aspects of mevalonate pathway inhibitors as antitumor agents". ... The first agent they identified was mevastatin (ML-236B), a molecule produced by the fungus Penicillium citrinum. ... Several combination preparations of a statin and another agent, such as ezetimibe/simvastatin, are also available. In 2005, ...
... "centrally acting agents",[10] but adds a distinct category of "directly acting agents", for dantrolene.[11] Use of this ... Several of these agents also have abuse potential, and their prescription is strictly controlled.[22][23][24] ... However, it is now known not every agent in this class has CNS activity (e.g. dantrolene), so this name is inaccurate.[5] ... "M03B Muscle Relaxants, Centrally acting agents". ATC/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology.. ...
This network is made up of protein-protein interactions from Treponema pallidum, the causative agent of syphilis and other ... Targets in synapses can be modulated with pharmacological agents. In this case, cholinergics (such as muscarine) and ...
Although these agents operate by different mechanisms, many of them can have similar impact upon the course of a condition.[6] ... "antirheumatic" at Dorland's Medical Dictionary. *^ Buer, Jonas Kure. 2015. "A history of the term "DMARD"." ... The term "antirheumatic" can be used in similar contexts, but without making a claim about an effect on the course.[3] Other ... Disease-modifying antirheumatic drugs (DMARDs) is a category of otherwise unrelated drugs defined by their use in rheumatoid ...
Antidementia Agents • Antidepressants • Antimigraine Agents • Antiparkinson's Agents • Antipsychotics • Anxiolytics • ... Anabolic steroids • Anti-inflammatories (NSAIDs) • Antirheumatics • Corticosteroids • Muscle relaxants • Bisphosphonates. Brain ... Analgesics • Anesthetics (General, Local) • Anorectics • Anti-ADHD Agents • Antiaddictives • Anticonvulsants • ...
Antidementia Agents • Antidepressants • Antimigraine Agents • Antiparkinson's Agents • Antipsychotics • Anxiolytics • ... Anabolic steroids • Anti-inflammatories (NSAIDs) • Antirheumatics • Corticosteroids • Muscle relaxants • Bisphosphonates. Brain ... Norepinephrine-dopamine releasing agents (NDRAs). Amfetamini • Befuraline • Lisdexamfetamine • Methamphetamine • Phenethylamine ... Analgesics • Anesthetics (General, Local) • Anorectics • Anti-ADHD Agents • Antiaddictives • Anticonvulsants • ...
A contrast agent is injected into the parotid duct, which opens from the cheek into the vestibule of the mouth opposite the ... disease-modifying antirheumatic drugs (DMARDs) such as methotrexate may be helpful. Hydroxychloroquine (Plaquenil) is another ... exogenous agents have been implicated in the pathogenesis of SS, such as Epstein-Barr virus (EBV), human T-lymphotropic virus 1 ... and human T-cell leukemia virus-1 are among the most studied infectious agents in SS.[15] Damaged self-structures targeted for ...
39 Studies found for: Ewing Sarcoma , Antirheumatic Agents. Also searched for Antirheumatic and Sarcoma, Ewings. See ...
EXPAND[Concept] ( AREA[ConditionSearch] Testicular Leukemia AND AREA[InterventionSearch] Antirheumatic Agents ). Help ...
Rheumatoid Arthritis: Trends in Antirheumatic Drug Use, C-reactive Protein Levels, and Surgical Burden Alma B. Pedersen, Anil ... Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients ... The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with ... Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and ...
Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying Antirheumatic Drugs in ...
A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biologic agents ... A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biologic agents ... Objective: Treatments for psoriatic arthritis (PsA) range from high-cost agents like tumour necrosis factor (TNF) inhibitors ... Results: We identified 32 potentially relevant RCTs; 14 were excluded because they involved unused agents, were unblinded, were ...
Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate ... Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate ... Anti-TNF agents provided a significant higher probability of achieving an ACR50 response at 6 months than the non-anti-TNF ... If more than one RCT was available for a given agent, the data were pooled across the trials using the random effect model ( ...
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 ...
"Antirheumatic Agents" by people in this website by year, and whether "Antirheumatic Agents" was a major or minor topic of these ... "Antirheumatic Agents" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Antirheumatic Agents" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Antirheumatic Agents". ...
Safe Use of Antirheumatic Agents in Patients with Comorbidities. Together they form a unique fingerprint. * Antirheumatic ... Safe Use of Antirheumatic Agents in Patients with Comorbidities. / Makol, Ashima; Wright, Kerry; Matteson, Eric L. ... Makol, A., Wright, K., & Matteson, E. L. (2012). Safe Use of Antirheumatic Agents in Patients with Comorbidities. Rheumatic ... Makol, Ashima ; Wright, Kerry ; Matteson, Eric L. / Safe Use of Antirheumatic Agents in Patients with Comorbidities. In: ...
Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and ... Objective: To examine the effects of biologic agents and other Disease-Modifying Antirheumatic Drugs (DMARDs) used to treat ... Objective: To examine the effects of biologic agents and other Disease-Modifying Antirheumatic Drugs (DMARDs) used to treat ... Title:Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and ...
Penicillamine is a chelating agent used in the treatment of Wilsons disease. It is also used to reduce cystine excretion in ...
The Impact of Seropositivity on the Effectiveness of Biologic Anti-Rheumatic Agents. Rheumatology (Oxford, England). ... The Impact of Seropositivity on the Effectiveness of Biologic Anti-Rheumatic Agents Rheumatology (Oxford) · April 15, 2021 ... The Impact of Seropositivity on the Effectiveness of Biologic Anti-Rheumatic Agents: Results From a Collaboration of 16 ...
Anti-Inflammatory Agents / administration & dosage * Antirheumatic Agents / administration & dosage* * Arthritis, Rheumatoid / ... Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic ... the delay from the onset of symptoms to the institution of disease-modifying antirheumatic drug (DMARD) therapy, 2) two ...
... was safe and effective in reducing articular and systemic symptoms in patients with an inadequate response to these agents. ... Antirheumatic Agents / adverse effects * Antirheumatic Agents / therapeutic use* * Arthritis, Rheumatoid / drug therapy* ... the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study Arthritis Rheum. 2008 Oct;58 ... was safe and effective in reducing articular and systemic symptoms in patients with an inadequate response to these agents. ...
Antirheumatic Agents. Grant support. *R01-HS-8517/HS/AHRQ HHS/United States ...
Antirheumatic Agents/therapeutic use*. *Arthritis, Rheumatoid/diagnostic imaging*. *Arthritis, Rheumatoid/drug therapy* ... remission can be achieved with tight control of inflammation and early use of disease modifying agents. The importance of ...
3. Analgesics, Narcotic antagonists, and agents used to treat arthritis: Agents used to treat gout. Antirheumatic agents. Mild ... Antifungal agents. Antileprosy agents. Antimalarial agents. Antiprotozoal agents. Antitubercular agents --. 2. Agents affecting ... Antifungal agents. Antileprosy agents. Antimalarial agents. Antiprotozoal agents. Antitubercular agents -- 2. Agents affecting ... Oxytocic agents --. 9. Homeostatic and nutrient agents: Agents used to treat hyperglycemia. Vitamins --. 10. Agents used to ...
Antiinflammatory/antirheumatic agents in combination , Antiinflammatory and antirheumatic products Brokerage service for ... Antiinflammatory/antirheumatic agents in combination. *Antiinflammatory/antirheumatic agents in combination with ... Agents acting on the renin-angiot.. Ace inhibitors, plain Ace inhibitors, plain ... Beta blocking agents Beta blocking agents Beta blocking agents, non-selecti.. Beta blocking agents, selective ...
2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents ...
Antiinflammatory and antirheumatic products non-steroids , Antiinflammatory and antirheumatic products Brokerage service for ... Agents acting on the renin-angiot.. Ace inhibitors, plain Ace inhibitors, plain ... Beta blocking agents Beta blocking agents Beta blocking agents, non-selecti.. Beta blocking agents, selective ... Other antiinflammatory and antirheumatic agents non-steroids , ... Lipid modifying agents Lipid modifying agents, plain Hmg coa ...
M01B Anti-inflammatory/antirheumatic agents in combination. M01BA Anti-inflammatory/antirheumatic agents in combination with ... M01BX Other anti-inflammatory/antirheumatic agents in combination with other drugs. M01C Specific antirheumatic agents. M01CA ... M01CC Penicillamine and similar agents. M01CC01 Penicillamine. M01CC02 Bucillamine. M01CX Other specific antirheumatic agents. ... M01AX Other anti-inflammatory and antirheumatic agents, non-steroids. M01AX01 Nabumetone. M01AX02 Niflumic acid. M01AX04 ...
Dermatologic Agents. Enzyme Inhibitors. Folic Acid Antagonists. Immunosuppressive Agents. Immunologic Factors. Antirheumatic ... Abortifacient Agents, Nonsteroidal. Abortifacient Agents. Reproductive Control Agents. Physiological Effects of Drugs. ... Previous treatment with any conventional or biologic Disease-modifying anti rheumatic drugs (DMARD) ...
Anti-Inflammatory Agents, Non-Steroidal. Anti-Inflammatory Agents. Antirheumatic Agents. Cyclooxygenase Inhibitors. Enzyme ... Sensory System Agents. Peripheral Nervous System Agents. Physiological Effects of Drugs. Antipyretics. ...
4. Ramsey-Goldman R, Schilling E. Optimum use of disease-modifying and immunosuppressive antirheumatic agents during pregnancy ... Antirheumatic drugs in pregnancy and lactation. Baillieres Clin Rheumatol. 1990;4:157-71. PMID: 2282661 ...
Peripheral Nervous System Agents. Physiological Effects of Drugs. Anti-Inflammatory Agents. Antirheumatic Agents. ... Anti-Inflammatory Agents, Non-Steroidal. Analgesics, Non-Narcotic. Analgesics. Sensory System Agents. ...
Antirheumatic Agents Gastrointestinal Agents Administrative Information. LactMed Record Number. 752 Last Revision Date. ... A total of 102 women were exposed to an anti-TNF agent and 59 were exposed to a thiopurine plus an anti-TNF agent. The use of ... Detection of biologic agents in breast milk and implication for infection, growth and development in infants born to women with ... Infants exposed to both a thiopurine and an anti-TNF agent had a 50% increase in the number of infections between 9 and 12 ...
IL-6 blocking agents also showed improvement in localized bone loss not seen with anti-TNF agents. There are a few studies with ... Kim SY, Schneeweiss S, Liu J, Solomon DH (2012) Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk ... Studies with anti-TNF blocking agents show preservation or increase in spine and hip BMD and also a better profile of bone ... 2016) Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatol ...
Disease-modifying antirheumatic drugs (DMARDS) have been used in the treatment of rheumatoid arthritis for a number of years. ... Edmonds J. Reclassification of antirheumatic agents: how and why. Clin Immunother 1994; 1: 110-6 ... Do Disease-Modifying Antirheumatic Drugs Actually Modify Disease Course in Rheumatoid Arthritis?. *Leo B. A. van de Putte. 1. ... Disease-modifying antirheumatic drugs (DMARDS) have been used in the treatment of rheumatoid arthritis for a number of years. ...
disease-modifying anti-rheumatic agents (DMARDs). *biologics (genetically engineered proteins made from human genes) ...
www.sigmaaldrich.com, Anti-inflammatory agents, Antimineralocorticoids, Pharmaceuticals, Anti-inflammatory and antirheumatic ...
  • Background The availability of increasing numbers of biological agents for the treatment of rheumatoid arthritis (RA) offers several therapeutic options. (bmj.com)
  • In rheumatoid arthritis (RA), patients with inadequate responses (IR) to conventional disease-modifying antirheumatic drugs (DMARDs), have benefited from biological agents that target various elements involved in the pathogenesis of RA: tumour necrosis factor (TNF) with anti-TNF agents (infliximab, adalimumab, certolizumab and golimumab and etanercept), T cells with anti-cytotoxic T lymphocyte antigen 4 antibodies (abatacept), B cells with anti-CD20 antibodies (rituximab) or interleukin (IL)-6 (tocilizumab). (bmj.com)
  • Systematic Review of Recommendations on the Use of Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer. (viictr.org)
  • Uhrenholt L, Schlemmer A, Hauge EM, Christensen R, Dreyer L, Suarez-Almazor ME, Kristensen S. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial). (viictr.org)
  • To study the impacts of 1) the delay from the onset of symptoms to the institution of disease-modifying antirheumatic drug (DMARD) therapy, 2) two treatment strategies (treatment with a combination of DMARDs or with a single drug), and 3) the presence of HLA-DRB1 alleles (shared epitope) on the prediction of disease remission after 2 years in patients with early rheumatoid arthritis (RA). (nih.gov)
  • To examine the efficacy and safety of the humanized anti-interleukin-6 receptor antibody tocilizumab combined with conventional disease-modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis (RA). (nih.gov)
  • Do Disease-Modifying Antirheumatic Drugs Actually Modify Disease Course in Rheumatoid Arthritis? (springer.com)
  • Disease-modifying antirheumatic drugs (DMARDS) have been used in the treatment of rheumatoid arthritis for a number of years. (springer.com)
  • Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis. (springer.com)
  • Wolfe F, Hawley D, Cathey M. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14 year-prospective evaluation of 1017 starts. (springer.com)
  • van de Putte, L.B.A., van Riel, P.L.C.M. Do Disease-Modifying Antirheumatic Drugs Actually Modify Disease Course in Rheumatoid Arthritis? (springer.com)
  • For patients with rheumatoid arthritis (RA), remission can be achieved with tight control of inflammation and early use of disease modifying agents. (nih.gov)
  • agent that relieves or prevents rheumatic disease, especially rheumatoid arthritis. (fpnotebook.com)
  • Rheumatoid arthritis (RA) is associated with increased risk of infections due to the disease per se and the use of antirheumatic treatments. (bmj.com)
  • While the outcome from trials with such agents in rheumatoid arthritis in particular has not been as would have been hoped, these results as with cy- closporin A and low-dose methotrexate in the therapy of rheumatoid arth- ritis have given us important indications for the approach employing what are generally described as "immunomodulators" to control this disease. (springer.com)
  • Auranofin is an antirheumatic agent, prescribed for rheumatoid arthritis. (medindia.net)
  • Fenoprofen is a non-steroidal anti-inflammatory agent, prescribed for pain and relief from rheumatoid arthritis and osteoarthritis. (medindia.net)
  • Flurbiprofen is a non-steroidal anti-inflammatory agent (NSAIA), prescribed for pain, tenderness, swelling, and stiffness caused by osteoarthritis (arthritis caused by a breakdown of the lining of the joints) and rheumatoid arthritis (arthritis caused by swelling of the lining of the joints), inflammation of eye, dysmenorrhea. (medindia.net)
  • Gold Sodium Thiomalate is an antirheumatic agent, prescribed for rheumatoid arthritis. (medindia.net)
  • A handout on this topic is available at https://familydoctor.org/familydoctor/en/diseases-conditions/rheumatoid-arthritis.html . (aafp.org)
  • Earlier diagnosis of rheumatoid arthritis allows for earlier treatment with disease-modifying antirheumatic agents. (aafp.org)
  • Rationale Anti-tumour necrosis factor (TNF) agents and other anti-rheumatic medications increase the risk of TB in rheumatoid arthritis (RA). (bmj.com)
  • The aim of this study was to explore the persistence of an antibody response 1.5 years after vaccination with 7-valent pneumococcal conjugate vaccine in patients with rheumatoid arthritis (RA) or spondyloarthropathy (SpA) treated with different antirheumatic drugs. (nih.gov)
  • Rapid diagnosis of rheumatoid arthritis allows for earlier treatment with disease-modifying antirheumatic drugs, which is associated with better outcomes. (aafp.org)
  • Methotrexate is typically the first-line agent for rheumatoid arthritis. (aafp.org)
  • Methotrexate should be the first-line disease-modifying antirheumatic drug in patients with rheumatoid arthritis unless there are contraindications. (aafp.org)
  • Patients who are in remission from rheumatoid arthritis for more than six months and on stable medication regimens are candidates for tapering or discontinuing disease-modifying antirheumatic drug or biologic treatment. (aafp.org)
  • Treatments for psoriatic arthritis (PsA) range from high-cost agents like tumour necrosis factor (TNF) inhibitors evaluated in large randomised control trials (RCTs) and low-cost disease modifying anti-rheumatic drugs (DMARDs) studied in less detail. (bmj.com)
  • Objective: To examine the effects of biologic agents and other Disease-Modifying Antirheumatic Drugs (DMARDs) used to treat psoriasis and psoriatic arthritis on cardiovascular risk factors and adverse cardiovascular outcomes. (eurekaselect.com)
  • Tocilizumab combined with any of the DMARDs evaluated was safe and effective in reducing articular and systemic symptoms in patients with an inadequate response to these agents. (nih.gov)
  • Whether treatment with combinations of DMARDs is superior to treatment with single agents is the subject of ongoing studies. (springer.com)
  • The study included traditional disease-modifying anti-rheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids. (news-medical.net)
  • Predictors of high costs were calculated, and an algorithm was constructed to predict future need for TNFinhibitor treatment in patients not responding to traditional disease-modifying antirheumatic drugs (DMARDs). (diva-portal.org)
  • More definitive treatment for RA consists of disease-modifying anti-rheumatic drugs (DMARDs) and targeted biologic agents. (healthline.com)
  • In a randomized trial of patients who were on stable disease-modifying antirheumatic drug (DMARD) regimens and in clinical remission for at least six months, 84% of patients who continued full DMARD treatment remained in remission after 12 months, compared with 61% who tapered DMARDs by 50%, and with 48% of those who stopped all DMARDs. (aafp.org)
  • This presents challenges for drug treatment of these conditions and for the effectiveness of conventional agents such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying anti-rheumatic drugs (DMARDs), anti-cytokine and other biologic agents, as well as natural products (or nutraceuticals). (springer.com)
  • Disease-modifying antirheumatic drugs (DMARDS) are immunomodulatory agents that act as immunosuppressives and cytotoxic and anti-inflammatory medications. (medscape.com)
  • Antirheumatic treatment, in particular longterm use of glucocorticoids, but also traditional disease modifying antirheumatic drugs (DMARD) and biological remedies have all been shown to increase risk of infections 4 , 5 , 6 . (jrheum.org)
  • The guidelines focus on the use of Disease Modifying AntiRheumatic Drugs (DMARD) and biologic agents. (associationdatabase.com)
  • Most treatments include the disease modifying anti-rheumatic agent (DMARD) methotrexate (Trexall), an anti-TNF inhibitor, or both. (healthline.com)
  • The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. (onmedica.com)
  • Patients taking biologic agents should be tested for hepatitis B, hepatitis C, and tuberculosis. (aafp.org)
  • Biologic agents, such as tumor necrosis factor inhibitors, are generally considered second-line agents or can be added for dual therapy. (aafp.org)
  • However, more than one biologic agent should not be used at one time (e.g., adalimumab [Humira] with abatacept [Orencia]) because of the high risk of adverse effects. (aafp.org)
  • Additional disease-modifying antirheumatic drugs or biologic agents should be added if disease activity persists. (aafp.org)
  • 3. Analgesics, Narcotic antagonists, and agents used to treat arthritis: Agents used to treat gout. (worldcat.org)
  • In addition, the efficacy of SPA as a therapeutic agent was evaluated in murine collagen-induced arthritis (CIA). (biomedsearch.com)
  • Thus, therapeutic agents designed to harness all of these properties may be an effective treatment for arthritis, by targeting both the innate inflammatory response and prodestructive pathways. (biomedsearch.com)
  • Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. (nih.gov)
  • 0.001).After initial increase, 1.5 years after pneumococcal vaccination with 7-valent conjugate vaccine, postvaccination antibody levels decreased significantly, reaching levels before vaccination in this cohort of patients with established arthritis treated with different antirheumatic drugs.EudraCT EU 2007-006539-29 and NCT00828997. (nih.gov)
  • After initial increase, 1.5 years after pneumococcal vaccination with 7-valent conjugate vaccine, postvaccination antibody levels decreased significantly, reaching levels before vaccination in this cohort of patients with established arthritis treated with different antirheumatic drugs. (nih.gov)
  • However, vaccine coverage among patients with RA, including those treated with anti-tumor necrosis factor (TNF) agents is still low 7 , 8 . (jrheum.org)
  • Antirheumatic drugs in pregnancy and lactation. (drugs.com)
  • The first line of treatment for RA is with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), usually methotrexate [ 11 , 12 ]. (hindawi.com)
  • In persons with RA, combination therapy with two or more disease-modifying antirheumatic drugs is more effective than monotherapy. (aafp.org)
  • In the past, further therapy using disease modifying antirheumatic drugs was only prescribed when there was radiographic evidence of erosions (holes in bones). (bmj.com)
  • Disease modifying antirheumatic drugs were thought to reduce the damage shown on radiographs (disease modification), but although objective evidence for this effect was hard to obtain, proof has now been unequivocally shown. (bmj.com)
  • Disease modifying antirheumatic drugs are thought to act by direct or indirect inhibition of cytokines, unlike non-steroidal anti-inflammatory drugs, which act mainly by inhibiting cyclooxygenase and thereby reducing the production of inflammatory prostaglandins (inhibiting symptoms but not influencing structural damage). (bmj.com)
  • The most commonly used disease modifying antirheumatic drugs were gold, penicillamine, and sulfasalazine, all of which produced a slow response and a high level of toxicity. (bmj.com)
  • The addition of methotrexate to the armamentarium, especially when rheumatologists started to use higher doses, produced an improvement, but still less than 50% of patients remained on disease modifying antirheumatic drugs treatment long term. (bmj.com)
  • One of the central elements in understanding the modes of action of various anti-inflammatory agents is the recognition that drugs may be limited in their effectiveness, selectivity and toxicology as a consequence of the disease processes themselves. (springer.com)
  • The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. (springer.com)
  • Viscoat is a brand name medication included in a group of medications called Other antiinflammatory and antirheumatic agents, non steroids . (rxwiki.com)
  • This group comprises antiinflammatory and antirheumatic preparations for systemic use. (whocc.no)
  • Combinations of antiinflammatory/antirheumatic agents (e.g. corticosteroids) are classified in M01B. (whocc.no)
  • Antiinflammatory or antirheumatic agents in combination with opioids are classified in N02AJ - Opioids in combination with non-opioid analgesics. (whocc.no)
  • Combined cold preparations with therapeutic levels of antiinflammatory agents are classified in this group at separate 5th levels by using the 50-series. (whocc.no)
  • The effect of disease characteristics (eg, joint erosions, disease duration and activity), different antirheumatic treatments and smoking on SAB risk will be evaluated. (bmj.com)
  • Penicillamine is a chelating agent used in the treatment of Wilson's disease. (pharmacycode.com)
  • 7. Hormones and agents affecting hormonal mechanisms: Adrenal corticosteroids. (worldcat.org)
  • 4. Ramsey-Goldman R, Schilling E. Optimum use of disease-modifying and immunosuppressive antirheumatic agents during pregnancy and lactation. (drugs.com)
  • Incident patients with RA are identified in the Danish National Patient Registry (DNPR) and the nationwide rheumatology registry, DANBIO, in which information on, for example, antirheumatic treatments, disease characteristics and smoking is collected prospectively in routine care. (bmj.com)
  • group B (infliximab, adalimumab or certolizumab) and group AB (both a thiopurine and an anti-TNF agent). (drugs.com)
  • 6 There has been considerable debate as to whether treatment of patients with GORD should be initiated with H 2 -receptor antagonists and "stepped up" to more effective agents if treatment fails, or if it should commence with proton-pump inhibitors, currently the most effective therapy, and then be "stepped down" when symptom control is achieved. (mja.com.au)
  • Not that long ago it was believed that antirheumatic therapy made little, if any, difference to the long term outcome of the disease. (bmj.com)
  • Antirheumatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (viictr.org)
  • Antimalarial agents. (worldcat.org)
  • Antimalarial agents may work through numerous proposed mechanisms in SLE, mediating subtle immunomodulation without causing overt immunosuppression. (medscape.com)
  • The objective of the present work was to compare the efficacy of biologicals (anti-tumour necrosis factor (TNF) agents, rituximab, abatacept, tocilizumab) in patients with RA with active disease and (i) an inadequate response (IR) to methotrexate (IR-MTX), (ii) an IR to anti-TNF agents (IR-anti-TNFs) using indirect comparisons. (bmj.com)
  • Makol, A , Wright, K & Matteson, EL 2012, ' Safe Use of Antirheumatic Agents in Patients with Comorbidities ', Rheumatic Disease Clinics of North America , vol. 38, no. 4, pp. 771-793. (elsevier.com)
  • The use of many of these agents is often limited by (a) the agents' unspecific actions or limited potency at their therapeutic targets, (b) their poor pharmacokinetic properties leading to poor bioavailability of the active agents, and (c) their varying array of serious and non-serious side-effects and adverse drug reactions. (springer.com)
  • However, when compared to specific biological agents, anti-TNFs demonstrated a higher probability of reaching an ACR50 than abatacept (OR 1.52, 95 % CI 1.0 to 2.28), but not in comparison to rituximab and tocilizumab. (bmj.com)
  • This group comprises specific antirheumatic preparations. (whocc.no)
  • Acetaminophen and hydrocodone is a combination of non-opioid and narcotic or sleep-inducing agents used to treat moderate to severe pain associated with inflammation. (medindia.net)
  • This 100% natural remedy combines two highly effective anti-inflammatory agents that work to reduce inflammation and swelling. (thefreedictionary.com)
  • In overall study, Ph.Chf and Ph.Sp have shown overwhelming results which signifies their potentials as sources of therapeutic agents against cancer. (frontiersin.org)
  • Similarly, the US Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) recommends these vaccines to all subjects ≥ 65 years and those treated with immunosuppressive agents 8 . (jrheum.org)
  • Central nervous system involvement and renal disease constitute more serious disease and often require high-dose steroids and other immunosuppressive agents, such as cyclophosphamide, azathioprine, or mycophenolate. (medscape.com)
  • ORLANDO -- Chronic use of nonsteroidal anti-inflammatory agents pro- motes sodium-retention weight gain and can cause blood pressure to rise by an average of 5 mm Hg, Dr. (thefreedictionary.com)
  • Nonsteroidal anti-inflammatory agents (NSAIDS) provide symptomatic relief for arthralgias, fever, headache, and mild serositis. (medscape.com)
  • Methods Randomised clinical trials were identified examining the efficacy of a biological agent in RA at 6 months in patients with an IR-MTX or with an IR-anti-TNF. (bmj.com)
  • The journal also aims to publish papers on the fundamental and clinical aspects of the iatrogenic conditions that accompany treatment with many anti-rheumatic agents including those involving the gastro-intestinal, hepato-renal and cardiovascular systems. (springer.com)
  • Doxorubicin is a highly efficacious and well-established anthracycline chemotherapeutic agent commonly used in the treatment of a wide range of cancers. (bireme.br)
  • As non-steroidal anti-inflammatory agents are commonly used and prescribed in emergency departments, it should be kept in mind that an acute dystonic reaction can develop against one of these agents, DKP. (thefreedictionary.com)
  • This agent is also commonly used for suppression and treatment of malaria. (medscape.com)